Ptc Therapeutics (PTCT) Other Accumulated Expenses (2012 - 2026)

Ptc Therapeutics' Other Accumulated Expenses history runs 15 years deep, the most recent figure standing at $13.6 million for Q2 2026.

• In Q2 2026, Other Accumulated Expenses fell 52.02% year-over-year to $13.6 million; the TTM figure through Jun 2026 stood at $13.6 million (down 52.02% YoY), while the FY2025 annual figure was $16.5 million, down 20.03% from the prior year.
• Other Accumulated Expenses for Q2 2026 stood at $13.6 million, down from $14.6 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $74.1 million in Q4 2023, with the low at $13.6 million in Q2 2026.
• The 5-year median for Other Accumulated Expenses is $28.6 million (2024), against an average of $30.4 million.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses soared 6034.0% in 2022, then plunged 72.21% in 2024.
• Ptc Therapeutics' Other Accumulated Expenses stood at $40.5 million in 2022, then surged by 82.78% to $74.1 million in 2023, then slumped by 72.21% to $20.6 million in 2024, then declined by 20.03% to $16.5 million in 2025, then declined by 17.56% to $13.6 million in 2026.
• Business Quant data shows PTCT's Other Accumulated Expenses at $13.6 million in Q2 2026, $14.6 million in Q1 2026, and $16.5 million in Q4 2025.